▲ +2.19% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Travere Therapeutics in the last 3 months. The average price target is $28.00, with a high forecast of $33.00 and a low forecast of $21.00. The average price target represents a 2.19% upside from the last price of $27.40.
The current consensus among 6 investment analysts is to buy stock in Travere Therapeutics. This Buy consensus rating has held steady for over two years.
Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. Its products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 8, 2008 and is headquartered in San Diego, CA.